康哲药业宣布,其自主研发的创新药物CMS-D017针对慢性肾病适应症的临床试验已获得监管机构批准。该进展标志着公司在肾病治疗领域的研发取得重要突破,为后续临床研究奠定基础。
康哲药业宣布,其自主研发的创新药物CMS-D017针对慢性肾病适应症的临床试验已获得监管机构批准。该进展标志着公司在肾病治疗领域的研发取得重要突破,为后续临床研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.